𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Influence of Chemotherapy on EGFR Mutation Status Among Patients With Non-Small-Cell Lung Cancer

✍ Scribed by Bai, H.; Wang, Z.; Chen, K.; Zhao, J.; Lee, J. J.; Wang, S.; Zhou, Q.; Zhuo, M.; Mao, L.; An, T.; Duan, J.; Yang, L.; Wu, M.; Liang, Z.; Wang, Y.; Kang, X.; Wang, J.

Book ID
115538200
Publisher
American Society of Clinical Oncology
Year
2012
Tongue
English
Weight
975 KB
Volume
30
Category
Article
ISSN
0732-183X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Gefitinib or Chemotherapy for Non–Small-
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
✍ Maemondo, Makoto; Inoue, Akira; Kobayashi, Kunihiko; Sugawara, Shunichi; Oizumi, πŸ“‚ Article πŸ“… 2010 πŸ› Massachusetts Medical Society 🌐 English βš– 341 KB

## Background: Non-small-cell lung cancer with sensitive mutations of the epidermal growth factor receptor (egfr) is highly responsive to egfr tyrosine kinase inhibitors such as gefitinib, but little is known about how its efficacy and safety profile compares with that of standard chemotherapy. ##